CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

THERAPEUTIC APHERESIS AND DIALYSIS is an esteemed journal published by Wiley, focusing on the fields of hematology and nephrology. Since its inception in 2003, the journal has provided a dedicated platform for research and advancements in therapeutic apheresis and dialysis methodologies, offering valuable insights for clinicians and researchers alike. With an ISSN of 1744-9979 and an E-ISSN of 1744-9987, the journal has established itself within Q3 in both the hematology and nephrology categories. Its Scopus rankings place it at #44 in nephrology and #79 in hematology, indicating its growing influence in these critical areas of medical research. Although it does not currently offer open access, THERAPEUTIC APHERESIS AND DIALYSIS remains a vital resource for professionals aiming to stay at the forefront of innovations and practices through 2024 and beyond. Researchers, healthcare professionals, and students are encouraged to engage with the latest findings and discussions presented within its pages, solidifying its role in enhancing patient care and therapeutic strategies.

Hematology Reports is an esteemed academic journal in the field of hematology, dedicated to advancing the understanding of blood disorders and their treatment. Published by MDPI, a leading Swiss publisher known for its commitment to open access since 2009, this journal provides a valuable platform for researchers and healthcare professionals to disseminate innovative findings and foster collaboration within the academic community. The journal features an array of articles ranging from clinical studies to laboratory research, and is indexed in Scopus, where it currently holds a rank of 113 out of 137 in the Medicine - Hematology category, placing it in the 17th percentile. As an open-access journal, Hematology Reports ensures that critical research is accessible to a global audience, supporting the dissemination of knowledge that has the potential to improve patient outcomes. This journal is an essential resource for those engaged in the study and treatment of hematological conditions, encouraging dialogue and the exchange of ideas to enhance clinical practices.

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

Case Reports in Hematology, published by HINDAWI LTD, stands as a prominent open-access journal dedicated to disseminating innovative case reports that contribute significantly to the field of hematology. Established in 2011, this journal provides a vital platform for researchers, practitioners, and clinicians to share detailed observations and novel findings related to blood disorders and treatment responses. With its commitment to high-quality research and accessibility, Case Reports in Hematology aims to enhance the understanding of hematological conditions, fostering collaboration and dialogue among professionals in the discipline. By leveraging an open-access model, the journal ensures that its valuable content is readily available to a global audience, consequently promoting advanced research and improving patient care in hematology. As a testament to its academic rigor and relevance, the journal appeals to its readership, which includes researchers, healthcare professionals, and students eager to expand their knowledge and insights into this critical area of medicine.

THROMBOSIS RESEARCH is a leading peer-reviewed journal in the field of hematology, published by PERGAMON-ELSEVIER SCIENCE LTD. With an impressive impact factor and ranked within the top 10 of 137 in its category according to Scopus, this journal provides a critical platform for the dissemination of innovative research related to thrombosis and hemostasis. Established in 1972, THROMBOSIS RESEARCH has been at the forefront of scholarly communication, addressing key issues, findings, and advancements over more than five decades. Recognized for its high-quality content, the journal is categorized in the Q1 quartile for 2023, reflecting its influence and relevance within the scientific community. Researchers, medical professionals, and students engaged in the study of blood disorders will find valuable insights and the latest discoveries within its pages. Although currently not an open-access publication, THROMBOSIS RESEARCH remains accessible to a wide audience through institutional subscriptions, ensuring that vital research continues to inform and enhance clinical practices around the globe.